The US IPO market seems to be hitting the pause button to recognize the holidays, with no companies on the calendar to price in the coming week. However, there is still a possibility that certain SPACs or Chinese deals launch early in the week to price by...read more
Six IPOs raised a combined $1.7 billion this past week, all of which began trading on Friday in the single busiest day of 2020 so far. API platform Agora (API) skyrocketed 153% in the best first day pop since 2019 IPO Beyond Meat (BYND)....read more
Akouos, a preclinical biotech developing gene therapies for inner ear disorders, raised $213 million by offering 12.5 million shares at $17, above the original range of $14 to $16, and in line with the ...read more
The 2020 US biotech IPO class closed Wednesday with an 80% average return from the offering price, a historic run-up for the year's 23 development-stage drug developers. The group has averaged a 36% pop on day one, and then 35% from there. Biotechs make up 70%...read more
US IPO Week Ahead: Time off for the Holidays
The US IPO market seems to be hitting the pause button to recognize the holidays, with no companies on the calendar to price in the coming week. However, there is still a possibility that certain SPACs or Chinese deals launch early in the week to price by...read more
US IPO Weekly Recap: Agora pops 153% while Albertsons falls flat in a 6 IPO week
Six IPOs raised a combined $1.7 billion this past week, all of which began trading on Friday in the single busiest day of 2020 so far. API platform Agora (API) skyrocketed 153% in the best first day pop since 2019 IPO Beyond Meat (BYND)....read more
Loud and clear: Hearing loss biotech Akouos prices upsized IPO above the range at $17 as biotech hot streak continues
Akouos, a preclinical biotech developing gene therapies for inner ear disorders, raised $213 million by offering 12.5 million shares at $17, above the original range of $14 to $16, and in line with the ...read more
2020 biotech IPOs now average an 80% return from their offer price
The 2020 US biotech IPO class closed Wednesday with an 80% average return from the offering price, a historic run-up for the year's 23 development-stage drug developers. The group has averaged a 36% pop on day one, and then 35% from there. Biotechs make up 70%...read more